How it works:
Apalutamide is an androgen receptor inhibitor that blocks androgen binding and prevents downstream signalling which fuels prostate cancer cell growth. This leads to delayed tumour progression and reduces the likelihood of metastases.
Recommended for:
Men with non-metastatic castration-resistant prostate cancer
Patients undergoing androgen deprivation therapy
Those requiring delay in metastasis development
As part of monitored oncological treatment
Non-metastatic castration-resistant prostate cancer
Metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
Take orally once daily, with or without food, at a dose prescribed by your oncologist. Regular clinical monitoring is advised throughout the course of treatment.
Hypersensitivity to apalutamide or formulation components
Severe hepatic impairment
History of seizures or conditions predisposing to seizures
Pregnancy and breastfeeding (indicated for men only)
Fatigue, general weakness
Rash, skin irritation
Bone fractures
Seizures
Thyroid function disturbances
Elevated blood lipids
Appetite loss
